Cell-free DNA as a biomarker in cancer
Author Information
Author(s): Eibl Robert H., Schneemann Markus
Primary Institution: Department of Internal Medicine, Hospitals of Schaffhausen, Switzerland
Hypothesis
Can circulating tumor DNA (ctDNA) be used as a reliable biomarker for earlier cancer detection and monitoring?
Conclusion
ctDNA has been shown to be a valid and independent biomarker for confirming and serial monitoring of cancer, enabling earlier and better treatment options.
Supporting Evidence
- ctDNA can predict the early recurrence of various cancers after initial therapy.
- Monitoring ctDNA levels can help avoid unnecessary treatments.
- ctDNA analysis allows for earlier detection of minimal residual disease.
Takeaway
Scientists are studying blood samples to find tiny pieces of DNA from tumors, which can help doctors catch cancer early and decide on the best treatments.
Methodology
The review discusses various methods of detecting circulating tumor DNA (ctDNA) and its clinical applications.
Limitations
Sensitivity of ctDNA diagnostics may be too low for general tumor screenings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website